BCAX
Bicara Therapeutics Inc. · Healthcare · Market cap $1.2B
Insiders sold $3.5M net in the last 90 days ·3 sellers, 0 buyers· 8 of 8 sales under Rule 10b5-1 plans· latest Form 4 filed Sep 10, 2026
Insider Buying
$4.8M
reported purchases (SEC code P)
Insider Selling
$9.9M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Latest filing
Sep 10, 2026
Cohlhepp Ryan
Bicara Therapeutics Inc. (BCAX) has 37 SEC Form 4 filings (105 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Sep 10, 2026.
Inside the rolling window, 5 insiders at Bicara Therapeutics Inc. reported 1 open-market purchase totaling $4.8M and 42 open-market sales totaling $9.9M. The most active filer is President, COO & Interim CEO Cohlhepp Ryan with 13 filings. Insiders have net sold $6.0M over the trailing 6 months. The most recent open-market filing is a sale of 17,500 shares by President, COO & Interim CEO Cohlhepp Ryan, dated Sep 8, 2026, worth $401K.
- Industry:Biotechnology
- CEO:Claire Mazumdar Clemon
- Employees:103
- HQ:Boston, MA, US
- IPO:2024-09-13
| Source | |||||||
|---|---|---|---|---|---|---|---|
| President, COO & Interim CEO | Sale | 17,500 | $401K | Sep 10 | -20.6% | SEC ↗ | |
| Chief Financial Officer | Sale | 12,500 | $350K | Aug 12 | -25.5% | SEC ↗ | |
| President and COO | Sale | 18,750 | $525K | Aug 12 | -25.5% | SEC ↗ | |
| Chief Executive Officer | Sale | 10,000 | $280K | Aug 12 | -25.5% | SEC ↗ | |
| Chief Executive Officer | Sale | 10,000 | $284K | Jul 14 | -34.7% | SEC ↗ | |
| Chief Financial Officer | Sale | 28,000 | $808K | Jul 10 | -36.5% | SEC ↗ | |
| President and COO | Sale | 28,214 | $818K | Jul 10 | — | SEC ↗ | |
| President and COO | Sale | 536 | $16K | Jul 10 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 9,200 | $188K | May 26 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $301K | May 20 | — | SEC ↗ | |
| President and COO | Sale | 12,500 | $254K | May 18 | — | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $126K | Apr 28 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 9,200 | $212K | Apr 22 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $354K | Apr 20 | — | SEC ↗ | |
| President and COO | Sale | 12,500 | $288K | Apr 17 | — | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $104K | Mar 26 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 9,200 | $170K | Mar 24 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 6,499 | $122K | Mar 20 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 6,905 | $130K | Mar 20 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 1,596 | $30K | Mar 20 | — | SEC ↗ | |
| President and COO | Sale | 12,500 | $246K | Mar 17 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 36,766 | $705K | Mar 11 | — | SEC ↗ | |
Mazumdar ClaireFirst in 3 months | Chief Executive Officer | Sale | 2,631 | $49K | Mar 6 | — | SEC ↗ |
Mazumdar ClaireFirst in 3 months | Chief Executive Officer | Sale | 1,786 | $33K | Mar 6 | — | SEC ↗ |
Mazumdar ClaireFirst in 3 months | Chief Executive Officer | Sale | 3,817 | $72K | Mar 6 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does BCAX have?
Bicara Therapeutics Inc. (BCAX) has 37 SEC Form 4 filings (105 transaction rows) in the rolling 365-day window, disclosed by 5 distinct insiders. Most recent filing: Sep 10, 2026.
When was the most recent SEC Form 4 filing for BCAX?
The most recent Form 4 filing for BCAX on Tracefour is dated Sep 10, 2026.
Who is the most active insider at BCAX?
The most active SEC Form 4 filer at BCAX in the rolling window is President, COO & Interim CEO Cohlhepp Ryan, with 13 filings.
What is the net insider flow at BCAX over the last 6 months?
Over the trailing 180 days, insiders at BCAX have net sold $6.0M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at BCAX in the current window?
Inside the rolling window, insiders at BCAX bought $4.8M and sold $9.9M based on SEC Form 4 filings.
Can I get alerts for BCAX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Bicara Therapeutics Inc. (BCAX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Bicara Therapeutics Inc. is in the Healthcare sector.